A recent meta-analysis reported that SGLT2 inhibitor use in diabetic patients was associated with significant reductions in LM, SMM, and SMI, raising concerns about increased sarcopenia risk accompanying weight loss [21]. Here, SLC5A2 is linked to sarcopenia.